Be aware or beware of wrong patient errors – part 2
October 1, 2024
PDL has recently released the Practice Alert ‘Be aware or beware of wrong patient errors – part 1’. This second alert follows up to provide
PDL has recently released the Practice Alert ‘Be aware or beware of wrong patient errors – part 1’. This second alert follows up to provide
From 1 October 2024, therapeutic vapes with a nicotine concentration of 20mg/mL or less will be available in pharmacies to patients 18 years or over
Notice is hereby given that the 112th Annual General Meeting of Pharmaceutical Defence Limited will be a hybrid meeting, both in person at Suite 3,
Pharmacists are likely aware that Wegovy® (semaglutide) is now available in Australia. The PDL Professional Officers have received several incident reports involving patients being supplied
The Wrong Patient incident type is a subset of dispensing incidents that continue to be highly reported to PDL. This almost entirely preventable error occurs
The Pharmacy Board of Australia’s revised Guidelines on compounding of medicines, which will take effect from 1 October 2024, is a timely reminder of the
PDL is delighted to sponsor the new Pharmacists’ Support Service (PSS) John Coppock Pharmacist Wellbeing Award, honouring the significant contribution of John to the wellbeing
The following vacancies will occur as of the date of the next Annual General Meeting to be held on Thursday, 17 October 2024. One Director
Understanding the click method PDL has become aware of a number of adverse events and health consequences from the popularised method of OZEMPIC® (semaglutide) administration
When pharmacists receive regulatory notifications, a range of common misconceptions can cloud their perception and impede their ability to respond effectively. Among these misconceptions are